The Company offers comprehensive one-stop service capabilities across the drug life cycle (drug discovery, development and manufacturing) for both small molecules and biologics and it is the fastest growing Indian CRDMO.
Its innovation-focused approach has enabled it to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
Wide specialty ingredients portfolio, well positioned to capitalize on the large market opportunity for niche specialty ingredients such as GLP-1, fermentation-based products,
Fully built-out automated manufacturing infrastructure with a consistent regulatory compliance track record.
Its business depends on the demand for the company CRDMO services, which contributed to 81.65% of its revenue from
operations in Fiscal 2025. Any adverse impact on its CRDMO customers' business or the industries in which they
operate may have a material adverse effect on the company business.
Developmental and commercial manufacturing contributed to 70.78% of its revenue from operations and 71.90%
of the company total number of Projects in Fiscal 2025. Its business may be adversely affected by a failures in early phase
developmental Projects or a failures to develop or manufacture commercially viable drugs, including for reasons
that are not within its control.
Its financial performance is dependent on the success of the molecules the company manufacture, and its revenue from
operations decreased in Fiscal 2023 compared to Fiscal 2022, partly attributable to the failures of a phase III
molecule and withdrawal of a commercialized molecule. Accordingly, any unfavorable developments affecting
these molecules' success rates, including failures to obtain the required regulatory approvals or withdrawal of
commercialized molecules, may have an adverse impact on its business, financial condition, results of operations
and prospects.
The company is subject to rapid advancements in technology which requires continuous investments. Its may not be
successful in developing new technologies and improving its existing technologies to maintain the company competitive
position. Any such failures to develop technologies may have a material and adverse impact on its business,
financial condition and results of operations.
The company is subject to extensive government regulations, and if its fail to obtain, maintain or renew our statutory and
regulatory licenses, permits and approvals required to operate the company business, results of operations and cash flows
may be adversely affected.
The company depends on certain key customers for a significant portion of its revenues (its top 5 and top 10 customers
contributed to 70.92% and 77.33%, respectively, of its revenue from operations in Fiscal 2025). Any inability to
retain the company key customers or decrease in revenues from any of its key customers could negatively affect the company business
and results of operations.
The company is dependent on its arrangements with DavosPharma, the affiliate of one of its Shareholders and also a
Selling Shareholder, for the company business and marketing activities in the United States.
The company faces the risk of losing manufacturing revenue from services supplied to innovator pharmaceutical companies
after the expiry of their patent protection period, which may lead to the availability of alternative formulations at a
lower cost.
The company is highly dependent on its skilled workforce, in particular its R&D team, for the company day-to-day operations. The
loss of, or its inability to attract or retain such persons may lead to knowledge loss and have a material adverse
effect on the company business performance.
The Offer Price of its Equity Shares, the company price-to-earnings ratio, its enterprise value to EBITDA ratio and the company
market capitalisation to total revenue from operations ratio may not be indicative of the trading price of its Equity
Shares upon listing on the Stock Exchanges subsequent to the Offer and, as a result, you may lose a significant
part or all of your investment.